INTRODUCTION: Monoclonal antibodies mark the beginning of a new era in the 
context of multiple myeloma (MM) treatment. Numerous antibodies have been tested 
or are currently in development for patients with MM, in order to improve 
tolerability and quality of life.
AREAS COVERED: This manuscript reviews emerging antibodies for the treatment of 
MM i.e. elotuzumab, daratumumab, MOR03087, isatuximab, bevacizumab, cetuximab, 
siltuximab, tocilizumab, elsilimomab, azintrel, rituximab, tositumomab, 
milatuzumab, lucatumumab, dacetuzumab, figitumumab, dalotuzumab, AVE1642, 
tabalumab, pembrolizumab, pidilizumab, nivolumab.
EXPERT OPINION: Amongst these antibodies, elotuzumab which targets SLAMF-7 and 
daratumumab which targets CD38, have been recently approved by FDA for patients 
with relapsed/refractory MM. Both agents are well tolerated. Multiple clinical 
trials incorporating these monoclonal antibodies in MM treatment are currently 
ongoing. Of special interest are the anticipated results of phase III clinical 
trials with elotuzumab [NCT0189164; NCT01335399; NCT02495922] and daratumumab 
[NCT02252172; NCT02195479] in newly diagnosed MM patients. Moreover, of great 
interest are the awaited data on pembrolizumabin combination with pomalidomide 
and dexamethasone in refractory/relapsed MM patients [NCT02576977] and in 
combination with lenalidomide and dexamethasone in newly diagnosed MM patients. 
It seems that the incorporation of monoclonal antibodies will change the 
landscape of myeloma therapy in the near future.